ARMP — Armata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $143.89m
- $403.45m
- $4.90m
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles
Health Rounds: Viruses may hold key to tackling deadly bacterial infection
Brief: Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver A Presentation At The 5th Annual Phage Futures Annual Meeting
Brief: Armata Pharmaceuticals Appoints David House As Principal Financial Officer
Brief: Armata Pharmaceuticals Announces Completion Of Enrollment Of Phase 2 Tailwind Study Of Inhaled AP-PA02 In Non-Cystic Fibrosis Bronchiectasis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
Brief: Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement With Innoviva
Brief: Armata Pharmaceuticals Promoted Richard Rychlik To Serve As Principal Financial Officer - SEC Filing
Brief: Armata Pharmaceuticals Announces New Financing And Leadership Transition
Brief: Armata Pharmaceuticals Announces New Financing And Leadership Transition
Brief: Armata Pharmaceuticals Announces First Quarter 2023 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Board Appoints Julianne Averill As Chief Financial Officer
Brief: Armata Pharmaceuticals Announces Q4 And Full-Year 2022 Results And Provides Corporate Update
Brief: Armata Pharma Announces Data From Phase 1B/2A Trial Of Inhaled AP-Pa02 In Patients With Cystic Fibrosis
Brief: Armata Pharmaceuticals Announces Completion Of Its Phase 1B/2A 'Swarm-P.A.' Study Of Inhaled AP-Pa02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
Brief: Armata Pharmaceuticals Announces Third Quarter 2022 Results